

A study to evaluate fetal and maternal outcome in pregnancy complicated by thrombocytopenia in a tertiary hospital

GpCapt JC Sharma, # DrPriyanka Sharma*, DrNeelimaChowdhury,\$
DrAnupoma ##, DrSonam Jindal.**

Prof & HOD (Obs&Gyn), ESIC medical college, Faridabad,

*Assistant prof, Obs&Gyn, ESIC medical college, Faridabad,

\$Assistant prof, Obs&Gyn, ESIC medical college, Faridabad,

Assistant prof, Obs&Gyn, ESIC medical college, Faridabad,

**Assistant prof, Obs&Gyn, ESIC medical college, Faridabad,

Correspondence author address: GpCapt JC Sharma, Prof & HOD (Obs&Gyn), ESIC medical college, Faridabad, Haryana, Pin121007.

Abstract

Introduction

Severe maternal thrombocytopenia during term pregnancy is fraught with the risk of hemorrhage at the time of delivery and the cesarean section with the additional risk of fetal thrombocytopenia. The study was planned to evaluate the incidence of thrombocytopenia and fetomaternal outcome in affected pregnancy.

Aim- To find the incidence of thrombocytopenia in pregnant women and analyze the maternal and fetal adverse outcome in affected women occurred in one year.

Material and method- It is a retrospective descriptive study of the medical record sheet of patients who had given birth at this tertiary institute during the period from 01 Jan 2019 to 31 Dec 2019. The data were collected from documents about history, examination, investigation report, delivery/ LSCS note, post-operative /postpartum status, baby birth weight, APGAR score, NICU admission, and neonatal death. The data were collected in an excel sheet and analyzed by statistical method.

Result: The incidence of thrombocytopenia in pregnancy was 7.1%, with mild in 5.6%, moderate in 1.1%, and severe in 0.4% cases. Gestational thrombocytopenia was observed in 107 (67.7%), primary ITP in 2 (1.2%), H pylori-associated ITP in 15 (9.4%), PIH/HELLP syndrome 23 (14.5%) and myelodysplasia –pancytopenia I (0.6%). There was no significant association between age and gravidity with thrombocytopenia. But a significant association with increasing parity was observed. Significant association of thrombocytopenia with anemia, normal delivery, PPH, low APGAR score, NICU admission was observed in the study. No significant association was observed of maternal age, gravidity, and birth weight with maternal thrombocytopenia. There was no case of neonatal intracranial hemorrhage in the observed group.

Conclusion

Thrombocytopenia second only to anemia, in pregnancy, is affected in 7.6% cases, with mild (5.6%), moderate (1.1%), and severe (0.4%) cases. An appropriate diagnosis and timely management of the serious condition provides an optimum outcome.

Keywords: pregnancy, thrombocytopenia, fetomaternal, outcome.

Date of Submission: 14-12-2020

Date of Acceptance: 28-12-2020

I. Introduction:

Platelet a very important blood corpuscle, has been observed to change the count within a range of 150–450 × 10⁹ per liter in healthy adults as measured either using a hemocytometer or by a counter. It has a short life span of 7-10 days in circulation. The range of count remains similar in pregnant and non-pregnant females but slightly lower level within the normal range in pregnant women towards the later part of pregnancy. Platelets, also called thrombocytes, in association with the coagulation factors react to bleeding from blood vessels due to trauma by clumping forming a blood clot. Platelets do not have a nucleus; they are fragments of cytoplasm enclosed in cell membrane derived from the megakaryocytes a large cell in the bone marrow. [1,2,3]. Platelet becomes activated before the formation of a clot. Circulating un-activated platelets are biconvex discoid structures, 2–3 μm in its greatest diameter. Activated platelets have cell membrane projections on the surface which help in clot formation. Megakaryocyte and platelet production is regulated by thrombopoietin, a hormone produced in the kidneys and liver. A megakaryocyte produces between 1,000 and 3,000 platelets in a lifetime. In a healthy adult, an average of 10¹¹ platelets is produced daily. Platelets are stored

in the spleen and are released by splenic contraction induced by the sympathetic nervous system. Low platelet counts below 150×10^9 per liter is termed as thrombocytopenia affects about 6.6%–11.6% of pregnant women.[4, 5] Causes of thrombocytopenia in pregnant women broadly may be divided into – a) conditions specific to pregnancy such as gestational thrombocytopenia (GT), preeclampsia/eclampsia, HELLP syndrome, and acute fatty liver of pregnancy; b) conditions non-specific to pregnancy such as pseudo-thrombocytopenia due to error in laboratory technique, primary immune thrombocytopenic purpura (ITP), secondary ITP associated to H pylori, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome (HUS); autoimmune diseases like lupus, anti-phospholipid syndrome; infections such as HIV, HBV, HCV, sepsis; disseminated intravascular coagulation; drug-related causes- heparin; von Willebrand disease Type IIb, bone marrow dysfunction, hypersplenism, nutritional deficiencies- vitamin B12, folate, etc. [6,7]

Although most of the cases of thrombocytopenia remain undiagnosed during pregnancy and complete the course of childbearing without any adverse fetal and maternal effects, occasional cases of severe maternal hemorrhage and very rarely fetal intracranial bleeding are encountered. The risk of fetal intracranial hemorrhage is feared to increase by head trauma occurring during the passage of the fetus through the birth canal during vaginal delivery in women with thrombocytopenia. But in practice the incidence was found to be low, less than 1% in a large study.[8,9]

The short life span of platelet along with rapid consumption and production reflect the health status of the women. The institution is located in a very poor socioeconomic area inhabited by a population affected by poverty, malnutrition, infestation, and poor hygienic environment. Several un-booked pregnant women complicated with a very low platelet count and significant anemia attend the hospital at odd hours in labor and put great stress on health care resources and sub-optimal fetomaternal outcome. The study was planned to evaluate the incidence of thrombocytopenia in pregnant women and fetomaternal outcome in affected pregnancy.

Aim - To find the incidence of thrombocytopenia in pregnant women and analyze the maternal and fetal adverse outcome in affected women occurred during the year 2019.

II. Material and method

It is a retrospective descriptive study of the medical record sheet of patients who had given birth at this tertiary institute during the period from 01 Jan 2019 to 31 Dec 2019. All the medical records of patients who were admitted for labor pain, irrespective of their booking status was included in the study. The data were collected from documents about history, examination, investigation report, delivery/ LSCS note, post-operative/postpartum status, baby birth weight, APGAR score, NICU admission, and neonatal death. The data were collected in the excel sheet and analyzed by statistical method.


III. Results

The total number of admission in the labor ward during the period was 2235. The standard procedure of assessment of the patient in labor was followed. The patients whose platelet count reported low on an automated machine less than 1.5 lac/ml were re-examined manually on counting chambers. The severity of Thrombocytopenia was graded as standard practice as (i) mild (1.5 -1 lac/ml), (ii) moderate- (1 - 0.5 lac/ml) and (iii) severe- (below 0.5 lac/ml). (10, [1]) They were investigated to evaluate the cause of thrombocytopenia from the past medical history of ITP, SLE, H pylori infection, myelodysplasia, malnutrition, history of treatment with heparin, blood test for complete hemogram, bleeding time, clotting time, renal function test, liver function test, HBsAg, HCV & HIV, dengue IgM serology, coagulation tests (PT, APTT, FDP, and fibrinogen). The labor was managed as per obstetrics protocol. Patients whose platelet count was less than 80 thousand were observed closely by repeated platelet count to find the pattern of change in the count. Those who had clinical features of H pylori infection were treated by a standard anti-H pylori drug regime. Oral steroid preparation was also used to improve the count. Those whose count fell to the very low level of less than 50,000/dL single donor platelet were harvested and transfused. General anesthesia was given in very low platelet count. Epidural analgesia was avoided. For vaginal delivery platelet count aimed to maintain above at 50,000/dl and for Cesarean section 80,000/dl. Another treatment was based on etiology. A maternal outcome like mode of delivery, the number of platelet transfusion, any complications were noted. Perinatal outcomes include live or stillbirth, complications like intrauterine growth restriction, low birth weight; 5 minute APGAR score, admission in NICU for birth asphyxia, neonatal death were observed. Six weeks postpartum platelet count was repeated.

The age group of 21-25 years constituted 42.3% of cases and 26-30 years constituted 33.2%, mean age was 26.03 SD was 4.62. (Table 1).

Table1. Age distribution of pregnant women.


AGE	Frequency	Percent	Mean	SD
<= 20 years	198	8.9%	26.03	4.62
21-25 years	945	42.3%		
26-30 years	742	33.2%		
> 30 years	348	15.6%		
Total	2233	100.0%		



The gravidity of the pregnant women was stratified, it was observed that primigravida constituted 31 %, second gravida 33%, thirdgravida, and more was 36.1%. (Table 2)

Table 2. Distribution of gravidity of pregnant women.


Gravidity	Frequency	Percent
Primigravida	692	31.0%
Second Gravida	736	33.0%
Third Gravida & Above	805	36.1%
Total	2233	100.0%



The parity of pregnant women was stratified, nullipara (35%), single child (38%), two-child (18%) as depicted. (Table no 3).

Table 3. Distribution of parity of pregnant women.


Parity	Frequency	Percent
No Child	802	35.9%
1 Child	869	38.9%
2 Children	420	18.8%
3 Children	113	5.1%
4 Children	20	0.9%
>4 Children	9	0.4%
Total	2233	100.0%



The hospital is located in a low socioeconomic area, anemia, and malnutrition prevalent in women. The pregnant women with anemia were observed in (15.6%) of cases. (Table 4)

Table 4. Distribution of anemia in pregnant women.


Anemia	Frequency	Percent
No	1885	84.4%
Yes	348	15.6%
Total	2233	100.0%



The pregnant women who were diagnosed as having low platelet by automated cell counter were put into re-examination by manual cell counter chamber. Thrombocytopenia was observed in 158 (7.1%) pregnant women: mild (5.6%), moderate (1.1%), and severe (0.4%). (Table 5)

Table 5. Distribution of Thrombocytopenia in pregnant women.

Thrombocytopenia	Frequency	Percent
Nil	2075	92.9%
Mild	125	5.6%
Moderate	25	1.1%
Severe	8	0.4%
Total	2233	100.0%




Total number of deliveries were 2233 of which normal delivery (56.8%), LSCS (28%), preterm labor (14.2%), forceps delivery (0.6%) and vacuum extraction (0.4%) was observed. (Table 6)

Table 6. Type of delivery

Delivery Type	Frequency	Percent
FTND (Full Term Normal Delivery)	1269	56.8%
LSCS (Caesarean)	626	28.0%
FORCEPS	14	0.6%
VACUUM	8	0.4%


PL (Preterm Labor)	316	14.2%
Total	2233	100.0%



Third stage complication such as severe PPH needing blood transfusion was observed in (0.9%) deliveries. (Table 7)

Table7. Distribution of severe PPH in pregnant women.

PPH (severe)	Frequency	Percent
Not Present	2213	99.1%
Present	20	0.9%
Total	2233	100.0%




The birth weight of the newborn was recorded by digital weight machine immediately after birth; birth weight less than 2.5 kg was taken as low birth weight in full-term deliveries. (Table 8)

Table 8. Distribution of birth weight in new born.

Child Birth Weight	Frequency	Percent
--------------------	-----------	---------


>=2.5 Kg	1395	62.5%
< 2.5 Kg	838	37.5%
Total	2233	100.0%



The health status of the newborn baby was assessed by APGAR score at 5 minutes. A score of more than 7 is considered as a healthy neonate needing no resuscitation; 6.7% of neonates needed resuscitation at birth. (Table 9)

Table 9. Distribution of APGAR score in newborn babies.


APGAR Score	Frequency	Percent
<7	149	6.7%
>=7	2084	93.3%
Total	2233	100.0%



The neonates who needed NICU admission for further management constituted (3.2%) of all new burns. (Table 10)

Table10. Distribution of NICU admission of newborn babies

NICU Admission	Frequency	Percent
No	2162	96.8%
Yes	71	3.2%
Total	2233	100.0%




Part B: Correlation of variables with Thrombocytopenia

- 1) Association of thrombocytopenia with the age of pregnant women: the statistical correlation of age and incidence of thrombocytopenia were examined. There was no correlation between age and incidence of thrombocytopenia as the p-value was greater than 0.05 (0.294). (Table 11)

Table.11 Correlation of Age and Thrombocytopenia


AGE	Thrombocytopenia									
	Frequency					%				
	Nil	Mild	Moderate	Severe	Total	Nil	Mild	Moderate	Severe	Total
<= 20 years	189	7	2	0	198	8.5%	0.3%	0.1%	0.0%	8.9%
21-25 years	872	58	12	3	945	39.1%	2.6%	0.5%	0.1%	42.3%
26-30 years	691	36	10	5	742	30.9%	1.6%	0.4%	0.2%	33.2%
> 30 years	323	24	1	0	348	14.5%	1.1%	0.0%	0.0%	15.6%
Total	2075	125	25	8	2233	92.9%	5.6%	1.1%	0.4%	100.0%
Chi-Square Value	10.738 ^a	Df	9	Sig.	0.294					



- 2) **Association of Thrombocytopenia with gravidity:** Association of thrombocytopenia in pregnant women was assessed by the statistical correlation with the incidence of thrombocytopenia were examined. There was no association was observed as the p-value was greater than 0.05 (0.458). (Table 12)

Table12.Correlation between Gravidity and Thrombocytopenia


Gravidity	Thrombocytopenia									
	Frequency					%				
	Nil	Mild	Moderate	Severe	Total	Nil	Mild	Moderate	Severe	Total
Primigravida	644	38	9	1	692	28.8%	1.7%	0.4%	0.0%	31.0%
Second gravida	692	37	5	2	736	31.0%	1.7%	0.2%	0.1%	33.0%
Third gravida& above	739	50	11	5	805	33.1%	2.2%	0.5%	0.2%	36.1%
Total	2075	125	25	8	2233	92.9%	5.6%	1.1%	0.4%	100.0%
Chi-Square Value	5.693 ^a	Df	6	Sig.	0.458					



3) **Association of Thrombocytopenia with parity:** Parity has shown a significant relationship with thrombocytopenia as the p-value is lesser than 0.05 (0.000). This infers that an increase in parity is associated with thrombocytopenia. (Table 13)

Table13. Correlation of parity and Thrombocytopenia


Parity	Thrombocytopenia									
	Frequency					%				
	Nil	Mild	Moderate	Severe	Total	Nil	Mild	Moderate	Severe	Total
No Child	746	46	9	1	802	33.4%	2.1%	0.4%	0.0%	35.9%
1 Child	810	45	10	4	869	36.3%	2.0%	0.4%	0.2%	38.9%
2 Children	395	24	1	0	420	17.7%	1.1%	0.0%	0.0%	18.8%
3 Children	101	9	3	0	113	4.5%	0.4%	0.1%	0.0%	5.1%
4 Children	16	1	2	1	20	0.7%	0.0%	0.1%	0.0%	0.9%
>4 Children	7	0	0	2	9	0.3%	0.0%	0.0%	0.1%	0.4%
Total	2075	125	25	8	2233	92.9%	5.6%	1.1%	0.4%	100.0%
Chi-Square Value	157.747 ^a	Df	15	Sig.	0.000					



4) **Association of Thrombocytopenia with anemia: the association between anemia and Thrombocytopenia was assessed statistically; the p-value was lesser than 0.05 (0.000).** This infers that the patients with anemia had a significant association with thrombocytopenia. (Table 13)

Table 13. Correlation of anemia and Thrombocytopenia


Anemia	Thrombocytopenia									
	Frequency					%				
	Nil	Mild	Moderate	Severe	Total	Nil	Mild	Moderate	Severe	Total
No	1803	73	8	1	1885	80.7%	3.3%	0.4%	0.0%	84.4%
Yes	272	52	17	7	348	12.2%	2.3%	0.8%	0.3%	15.6%
Total	2075	125	25	8	2233	92.9%	5.6%	1.1%	0.4%	100.0%
Chi-Square Value	157.637 ^a	Df	3	Sig.	0.000					



5) **Association of Thrombocytopenia with the type of delivery:** Type of delivery was assessed statistically; patients with Thrombocytopenia had more normal delivery as p-value lesser than 0.05 (0.013). (table 14)

Type of Delivery	Thrombocytopenia									
	Frequency					%				
	Nil	Mild	Moderate	Severe	Total	Nil	Mild	Moderate	Severe	Total


FTND	1179	73	11	6	1269	52.8%	3.3%	0.5%	0.3%	56.8%
LSCS	575	44	6	1	626	25.8%	2.0%	0.3%	0.0%	28.0%
FORCEPS	13	1	0	0	14	0.6%	0.0%	0.0%	0.0%	0.6%
VACUUM	6	2	0	0	8	0.3%	0.1%	0.0%	0.0%	0.4%
Preterm Labor	302	5	8	1	316	13.5%	0.2%	0.4%	0.0%	14.2%
Total	2075	125	25	8	2233	92.9%	5.6%	1.1%	0.4%	100.0%
Chi-Square Value	25.469 ^a	Df	12	Sig.	0.013					



6) **Association of Thrombocytopenia with PPH:** Patients with thrombocytopenia had a higher incidence of PPH as shown a significant relationship; as p-value was less than 0.05 (0.000). (Table 15)

Table 15. Correlation of postpartum hemorrhage and Thrombocytopenia


PPH	Thrombocytopenia									
	Frequency					%				
	Nil	Mild	Moderate	Severe	Total	Nil	Mild	Moderate	Severe	Total
Not Present	2061	122	24	6	2213	92.3%	5.5%	1.1%	0.3%	99.1%
Present	14	3	1	2	20	0.6%	0.1%	0.0%	0.1%	0.9%
Total	2075	125	25	8	2233	92.9%	5.6%	1.1%	0.4%	100.0%
Chi-Square Value	59.408 ^a	Df	3	Sig.	0.000					



7) **Association of Thrombocytopenia with birth weight:** Birthweightof the child and thrombocytopenia in pregnant women was assessed statistically; it shown no relationship of birth weight with thrombocytopenia as p-value is greater than 0.05 (0.260).(Table 16)

Table16. Correlation of Thrombocytopenia and birth weight

Child Birth Weight	Thrombocytopenia									
	Frequency					%				
	Nil	Mild	Moderate	Severe	Total	Nil	Mild	Moderate	Severe	Total
>=2.5 Kg	1303	72	16	4	1395	58.4%	3.2%	0.7%	0.2%	62.5%
< 2.5 Kg	772	53	9	4	838	34.6%	2.4%	0.4%	0.2%	37.5%
Total	2075	125	25	8	2233	92.9%	5.6%	1.1%	0.4%	100.0%
Chi-Square Value	1.914 ^a	Df	3	Sig.	0.591					




8) Association of thrombocytopenia with 5 minutes APGAR score:the association of patients with thrombocytopenia had a low 5 minute APGAR score statistically.The p-value lesser than 0.05 (0.000). This

infers that the baby born to patients with severe thrombocytopenia had low 5minutes APGAR Score. (Table 17)

Table17. Correlation of Thrombocytopenia and 5 minutesAPGAR score of neonates


5MAPG	Thrombocytopenia									
	Frequency					%				
	Nil	Mild	Moderate	Severe	Total	Nil	Mild	Moderate	Severe	Total
<7	134	7	5	3	149	6.0%	0.3%	0.2%	0.1%	6.7%
>=7	1941	118	20	5	2084	86.9%	5.3%	0.9%	0.2%	93.3%
Total	2075	125	25	8	2233	92.9%	5.6%	1.1%	0.4%	100.0%
Chi-Square Value	19.724 ^a	Df	3	Sig.	0.000					



9) Association of thrombocytopenia with NICU admission:the association of Thrombocytopenia and NICU admission of the newborn was assessed statically. Babies born of the thrombocytopenic mother had higher NICU admission significantly as p-value lesser than 0.05 (0.000). (Table 18)

Table18. Correlation of Thrombocytopenia in pregnancy and NICU admission

NICU admission	Thrombocytopenia									
	Frequency					%				
	Nil	Mild	Moderate	Severe	Total	Nil	Mild	Moderate	Severe	Total
No	2018	116	22	6	2162	90.4%	5.2%	1.0%	0.3%	96.8%
Yes	57	9	3	2	71	2.6%	0.4%	0.1%	0.1%	3.2%
Total	2075	125	25	8	2233	92.9%	5.6%	1.1%	0.4%	100.0%
Chi-Square Value	26.516 ^a	Df	3	Sig.	0.000					



The aetiology of thrombocytopenia were as gestational thrombocytopenia in 107 (67.7%), primary ITP in 2 (1.2%) , H pylori associated ITP in 25(15.8%), PIH/HELLP syndrome 23 (14.5%) and myelodysplasia–pancytopenia 1(0.6%).

Table 19: Etiology of Thrombocytopenia

Disease	Number	Percentage
Gestational Thrombocytopenia	107	67.7
PIH/HELLP Syndrome	23	14.5
Primary ITP	2	1.2
H pylori associated ITP in 15(5%),	15	9.4%
Pancytopenia	1	0.6
Total	158	100

Severe cases of thrombocytopenia were treated by platelet transfusion/single donor platelet, steroid, and blood transfusion in addition to standard obstetrics care. Ten neonates had an episode of thrombocytopenia and were treated by standard protocol. There was no case of intracranial hemorrhage in the newborn or neonatal death.

IV. Discussion:

Thrombocytopenia complicates pregnancy in a large number of women, the frequency of which is second only to anemia. A mild and moderate degree of thrombocytopenia is usually well tolerated by pregnant women with no fetomaternal complication. The gestational thrombocytopenia (GT) accounts for more than seventy percent of cases. It usually affects less severely and platelet count remains above about eighty thousand per milliliter. [11] The platelet count in GT usually returns to normal following a few months postpartum. A more severe degree of thrombocytopenia is observed in immune thrombocytopenia and pregnancy-induced hypertension /HELLP syndrome, thrombotic thrombocytopenic purpura TTP, DIC, and myelodysplastic disorders. The role of H pylori infection in inducing ITP is significant as it can be treated by standard treatment regimen and the improvement of platelet count is observed within a few weeks. The prevalence of H pylori infection in the general population is very high in unhygienic living conditions with poor sanitation facilities. In the Indian subcontinent prevalence of *H. pylori* can be as high as 80 percent or more in rural areas. The most common manifestation of *H. pylori* infection in India is peptic ulcer disease, with a predominance of duodenal ulcer disease, over gastric ulcers as high as 8:1 to 30:1. [12].

Immune thrombocytopenia is an uncommon cause of thrombocytopenia in pregnancy, low as 1 in 1000 and 1 in 10,000. In 30% of cases, it is diagnosed during pregnancy and childbirth. ITP develops related to viral infection (human immunodeficiency virus [HIV], hepatitis C, and *Helicobacter pylori*), autoimmune disease, and other challenges. Factors that induce primary ITP and why its course worsens in some pregnant patients are not well understood. H pylori infection-associated ITP is postulated to hypothesize that have been proposed regarding the mechanism by which *H. pylori* induces the development of ITP. One suggested theory is that cross-reactive antibody against H pylori to platelet surface antigen by molecular mimicry. [13]. Antiplatelet antibodies can cross the placenta and induce thrombocytopenia in the fetus. Many poorly understood factors such as the maturity of the fetal reticuloendothelial system, influence the development of fetal thrombocytopenia which

cannot be predicted using available clinical or laboratory parameters. A study had reviewed 788 patients with ITP, including 494 H pylori-infected patients collected from 17 studies, in 2007. Platelet counts increased in ITP patients who received eradication treatment, compared with untreated patients, and the weighted mean difference (WMD) in platelet count was $34.0 \times 10^9 /L$ regardless of the outcome of H. pylori eradication.[14,15,16]

The platelet counts increased significantly in H. pylori-infected patients after successful H. pylori eradication, compared with the following groups: untreated. Inconsistent correlation of neonatal thrombocytopenia was observed with the severity of maternal thrombocytopenia, the level of maternal platelet-associated immunoglobulin, maternal splenectomy, or several other parameters. The predictor of neonatal thrombocytopenia identified is a history of thrombocytopenia in the elder sibling. Up to 50% of women with preeclampsia may have thrombocytopenia, and its severity generally parallels. Occasionally, Thrombocytopenia may precede other manifestations of preeclampsia such as hypertension. Unlike preeclampsia, HELLP is more common in multiparous women. Thrombotic thrombocytopenic purpura (TTP) and HUS, collectively referred to as thrombotic microangiopathies (TMAs), are not pregnancy-specific, although they occur with increased frequency during or about pregnancy. TTP is strongly associated with a severe deficiency of ADAMTS-13, a metalloprotease that cleaves ultra-large von Willebrand factor (VWF) multimers, the most hemostatically active species of VWF. Deficiencies of ADAMTS-13 are usually acquired, resulting from neutralizing autoantibodies. ([17]

In another study from Europe, the prevalence of thrombocytopenia in pregnant women was 15.3% compared with 4% in controls. Most cases of thrombocytopenia were mild (76%), only 4% of the women with thrombocytopenia had severe thrombocytopenia.[18]

In all cases of thrombocytopenia, whether in pregnant or non-pregnant individuals, the peripheral blood film should be examined closely to evaluate for ethylenediaminetetraacetic acid-dependent platelet clumping, causing "pseudo-thrombocytopenia." In such cases, determination of the platelet count in a citrate tube may eliminate clumping and lead to more accurate readings.[19]

Disseminated intravascular coagulation (DIC) may arise from several events in pregnancy, such as placental abruption, amniotic fluid embolism, sepsis, uterine rupture causing a rapid release of tissue factor-rich material into the maternal circulation initiating activation of coagulation, with consumption of coagulation factors and severe hypo-fibrinogenemia and thrombocytopenia. hemolytic uremic syndromes (HUS), thrombotic thrombocytopenic purpura (TTP) are life-threatening diseases needing multispecialty involvement.

In the study, the incidence of thrombocytopenia was 7.1%, gestational thrombocytopenia in 107 (67.7%), primary ITP in 2 (1.2%), H pylori-associated ITP in 15 (9.4%), PIH/HELLP syndrome 23 (14.5%) and myelodysplasia –pancytopenia 1 (0.6%). There was no significant association between age and gravidity with thrombocytopenia. But a significant association with increasing parity was observed. Significant association of thrombocytopenia with anemia, normal delivery, PPH, low APGAR score, NICU admission was observed in the study. No significant association was observed with birth weight. The high incidence of H pylori-associated ITP is a preventable condition that can be treated by an appropriate anti-H pylori regimen for its complete eradication. A study conducted on pregnancy with thrombocytopenia in India had reported of 80.59% of cases were diagnosed to have gestational thrombocytopenia, 15% of cases had thrombocytopenia associated with hypertensive disorder/ HELLP syndrome. [20] A study in Africa had reported the prevalence of Thrombocytopenia in pregnant women as high as 15.3% compared with 4% in non-pregnant control. [21]

In another study had concluded the presence of gestational thrombocytopenia in 70-80%, hypertensive disorders for approximately 20%, and immune thrombocytopenic purpura for about 3-4% of all cases of thrombocytopenia in pregnancy.[22]

Management of thrombocytopenia in pregnancy, especially during pregnancy, near term, and at labor need judicious utilization of therapeutic options depending on the etiology which ranges from the administration of treatment of H pylori, immunosuppressant, steroid, intravenous immunoglobulin, high doses of Rh immunoglobulin, thrombopoietin mimetics, platelet transfusion, and plasmapheresis.[23,24,25,26,27,28]

V. Conclusion:

Pregnancy with thrombocytopenia is a relatively common condition in obstetrics practice, the gestational thrombocytopenia (67.7%) accounts for the majority of them followed by the hypertensive disorder of pregnancy and HELLP syndrome (14.5%), H pylori-associated Thrombocytopenia and (9.4%). primary ITP (1%). There was no significant association of age and gravidity with the prevalence of thrombocytopenia. But a significant association with increasing parity was observed. Significant association of thrombocytopenia with anemia, normal delivery, PPH, low APGAR score, NICU admission was observed in the present study. There was no case of neonatal intracranial hemorrhage in the observed group. No significant association was observed with the birth weight of neonate. Screening for thrombocytopenia, anemia, and H pylori infection during the

terminal part of pregnancy and timely intervention may improve the outcome and minimize serious maternal hemorrhage, fetal and neonatal complications.

Reference

- [1]. Bohlen F, Hohlfield P, Extermann P, Perneger TV, de Moerloose P. Platelet count at term pregnancy: a reappraisal of the threshold. *ObstetGynecol* 2000;95:29–33]
- [2]. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal Thrombocytopenia. *N Engl J Med* 1993;329:1463–6.
- [3]. Lee, J. S., Kim, N. Y., Na, S. H., Youn, Y. H. & Shin, C. S. Reference values of the neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea. *Medicine* 97, e11138–e11138, <https://doi.org/10.1097/MD.00000000000011138> (2018).
- [4]. Gernsheimer T, James AH, Stasi R, How I Treat Thrombocytopenia in pregnancy. *Blood*, 2013;121(1):38–47.
- [5]. Singh N, Dhakad A, Singh U, Tripathi, Sankhwar P. Prevalence and Characterization of Thrombocytopenia in Pregnancy in Indian Women. *Indian J Hematol Blood Transfus* 2012;28:77–81].
- [6]. The American College of Obstetrics and Gynecology: Practice Bulletin Thrombocytopenia in Pregnancy VOL. 128, NO. 3, SEPTEMBER 2016.]
- [7]. Fogerty AE. Thrombocytopenia in Pregnancy: Approach to Diagnosis and Management. *SeminThrombHemost.* 2020 Apr; 46(3):256–263.
- [8]. Pregnancy in patients with idiopathic thrombocytopenic purpura: assessing the risks for the infant at delivery. *Burrows RF, Kelton JG, ObstetGynecolSurv.* 1993 Dec; 48(12):781–8.
- [9]. Fujimura K, Harada Y, Fujimoto T, et al. Nationwide study of idiopathic thrombocytopenic purpura in pregnant women and the clinical influence on neonates. *Int J Hematol.* 2002;75(4):426.]
- [10]. Jeffrey A, Levy CPT, MC, FS, and Lance D. Murphy, MD, Thrombocytopenia in pregnancy, clinical review JABFP July–Aug 2002 Vol.15, No.4. 290–7.
- [11]. Zutshi V, Gupta N, Arora R, Dhanker S. Prevalence of gestational Thrombocytopenia and its effect on maternal and fetal outcome. *Iraqi J Hematol* 2019;8:21–4.
- [12]. Abraham P, Bhatia SJ. Position paper on *Helicobacter pylori* in India. Indian Society of Gastroenterology. *Indian J Gastroenterol.* 1997;16 (Suppl 1):S29–33
- [13]. Kuwana M. *Helicobacter pylori*-associated immune Thrombocytopenia: clinical features and pathogenic mechanisms. *World J Gastroenterol* 2014; 20(3): 714–723
- [14]. Franchini, M., Cruciani, M., Mengoli, C., Pizzolo, G. & Veneri, D. Effect of *Helicobacter pylori* eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. *J. Antimicrob. Chemother*(2007).60, 237–246.
- [15]. Kim, B. J., Kim, H. S., Jang, H. J. & Kim, J. H. *Helicobacter pylori* Eradication in Idiopathic Thrombocytopenic Purpura: A MetaAnalysis of Randomized Trials. *Gastroenterol. Res. Pract.* 2018, 6090878–6090878, <https://doi.org/10.1155/2018/6090878> (2018).
- [16]. Choi, K. Current Trends of *Helicobacter pylori* Eradication in Korea. *Korean J. Helicobacter Up. Gastrointest. Res.* 15, 147, <https://doi.org/10.7704/kjhugr.2015.15.3.147> (2015).
- [17]. Lee, S. W., Kim, H. J. & Kim, J. G. Treatment of *Helicobacter pylori* Infection in Korea: A Systematic Review and Meta-analysis. *J. Korean Med. Sci.* 30, 1001–1009, <https://doi.org/10.3346/jkms.2015.30.8.1001> (2015).
- [18]. Keith R McCrae. Thrombocytopenia in Pregnancy; Hematology 2010(1):397–402.
- [19]. Bizzaro, Nicola; PseudoThrombocytopenia: Pathology - Journal of the RCPA: 2009 - Volume 41 - Issue - p 34.
- [20]. Latika Sahu, Asmita Rathore, Vaishali Paliwal: A Clinical Study of Thrombocytopenia in Pregnancy. *IJSR - International Journal Of Scientific Research*; Volume: 4, Issue: 6, (2015) 738–740.
- [21]. Olayemi E, Akuffo FW. Gestational Thrombocytopenia among pregnant Ghanaian women. *Pan Afr Med J* 2012;12:34.
- [22]. Anca Marina CIOBANUa ; Simona COLIBABAa ; Brandusa CIMPOCAa ; Gheorghe PELTECUa,b; Anca Maria PANAITESCUa ; Thrombocytopenia in Pregnancy: MAEDICA – a Journal of Clinical Medicine 2016; 11(5): 55–60.)
- [23]. Rhd immune treatment [: Sieunarine K, Shapiro S, Al Obaidi M, Girling J. Intravenous anti-D immunoglobulin in the treatment of resistant immune thrombocytopenic purpura in pregnancy. *BJOG* 2007; 114:505–507.]
- [24]. A Care, S Pavord, M Knight, Z Alfirevic; Severe primary autoimmune Thrombocytopenia in pregnancy: a national cohort study. *BJOG*. Volume 125, Issue 5, April 2018; Pages 604–61.
- [25]. Neubert, C. et al. The American Society of Hematology 2011 evidence-based practice guideline for immune Thrombocytopenia. *Blood* 117, 4190–4207, <https://doi.org/10.1182/blood-2010-08-302984> (2011).
- [26]. Jang, J. H. et al. Management of immune Thrombocytopenia: Korean experts' recommendation in 2017. *Blood Res.* 52, 254–263.
- [27]. Harinder Gill, Garret M K Leung, David Lopes, Yok-Lam Kwong; The thrombopoietin mimetic eltrombopag and romiplostim in the treatment of refractory aplastic anemia. *Br J Haematol*, 2017 Mar; 176(6):991–994
- [28]. Kaufman RM et al. Platelet Transfusion: A Clinical Practice Guideline from the AABB. *Ann Intern Med.* 2015; Feb 03; 162(3):205–13.